BACKGROUND: Nowadays, non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in children. Our recent clinical trial demonstrated that dietary and VSL#3-based interventions may improve fatty liver by ultrasound and body mass index (BMI) after 4 months. OBJECTIVES: As in this short-term trial, as in others, it is impracticable to monitor response to therapy or treatment by liver biopsy, we aimed to identify a panel of potential non-invasive metabolic biomarkers by a urinary metabolic profiling. METHODS: Urine samples from a group of 31 pediatric NAFLD patients, enrolled in a VSL#3 clinical trial, were analyzed by highresolution proton nuclear magnetic resonance spectroscopy in combination with analysis of variance-Simultaneous Component Analysis model and multivariate data analyses. Urinary metabolic profiles were interpreted in terms of clinical patient feature, treatment and chronology pattern correlations. RESULTS: VSL#3 treatment induced changes in NAFLD urinary metabolic phenotype mainly at level of host amino-acid metabolism (that is, valine, tyrosine, 3-amino-isobutyrate or β-aminoisobutyric acid (BAIBA)), nucleic acid degradation (pseudouridine), creatinine metabolism (methylguanidine) and secondarily at the level of gut microbial amino-acid metabolism (that is, 2-hydroxyisobutyrate from valine degradation). Furthermore, some of these metabolites correlated with clinical primary and secondary trial end points after VSL#3 treatment: tyrosine and the organic acid U4 positively with alanine aminotransferase (R = 0.399, P = 0.026) and BMI (R = 0.36, P = 0.045); BAIBA and tyrosine negatively with active glucagon-like-peptide 1 (R = − 0.51, P = 0.003; R = -0.41, P = 0.021, respectively). CONCLUSIONS: VSL#3 treatment-dependent urinary metabotypes of NAFLD children may be considered as non-invasive effective biomarkers to evaluate the response to treatment.
INTRODUCTION
Unhealthy lifestyle choices have hastened an epidemic of childhood obesity, drastically impacting the state of pediatric health care. 1 Obesity is associated, in children as in adults, with a markedly increased risk of multiple diseases, such as type 2 diabetes mellitus and non-alcoholic fatty liver disease (NAFLD). Nowadays, NAFLD is one of the most common chronic liver diseases. It reaches a prevalence of 13% in the general pediatric population and up to 80% in obese children. 2 The disease ranges from intra-hepatic fat accumulation (steatosis) to the more severe form (non-alcoholic steatohepatitis (NASH)), characterized by steatosis together with inflammation and ballooning, and eventually fibrosis. 3 The development of NAFLD and its progression to NASH are complex processes linked to various and not fully understood genetic and environmental factors. 4 In this pathogenetic framework, the interaction between the liver and gut, the so called 'gut-liver axis', appears to have a major role. 5, 6 This relationship has been based on the evidence that there is a continuous bidirectional communication between these organs through the bile, hormones, inflammatory mediators and products of digestion and absorption. 7 During NAFLD development and progression, the ingestion of foods higher in refined sugar and fats may cause an increase in intestinal permeability (IP) and a consequent overwhelming presence of gut-derived microbial products, such as lipopolysaccharide, thus inducing endotoxemia and activating the innate immunity and the inflammation cascade. 6, 7 In fact, it has been largely demonstrated that the gut barrier of patients affected by obesity and NAFLD is altered, because of a tight junction disruption process leading to an increase in IP. 5 Furthermore, our group has demonstrated that IP and lipopolysaccharide circulating levels are significantly increased also in children with NAFLD and that these two parameters correlated with a higher severity of liver disease. 8, 9 An intriguing hypothesis to explain the nexus between liver and gut in NAFLD is that changes in gut microbiota composition may have a role of mediators of the effects of dietary habits providing a mirror of the intestinal and hepatic damage. 10 Therefore, as suggested by several authors, dietary and drug-based interventions that may modulate gut microbiota could be effective in the recovery of NAFLD-associated gut and liver damage. 11 The potential beneficial effects of probiotics, prebiotics and synbiotics have been confirmed in several experimental studies. [12] [13] [14] We have recently performed a randomized controlled trial (RCT) of VSL#3 in children with NAFLD and in the present study analyzed the same cohort. The authors observed an improvement of fatty liver-as evaluated by ultrasound-a significant decrease in the body mass index (BMI) and a significant increase of total and activated form of glucagon-like-peptide 1 (GLP-1) in VSL#3supplemented children, compared with the placebo group. 15 Although BMI, liver ultrasound and GLP-1 levels may provide a preliminary proof of response to VSL#3 in terms of steatosis, they have significant limitations in distinguishing simple steatosis from NASH, which could be currently evaluated exclusively by liver biopsy. As in this short-term trial, as in others, it is impossible to monitor response to therapy/treatment by liver biopsy, we sought not only to provide a panel of potential non-invasive metabolic biomarkers, usually reliable and reproducible and commonly used in providing diagnostic and prognostic panels, but also in tracing response to treatments as indicators. Indeed, metabolomics has the high potential to provide biomarkers from different fluids, by measuring hundreds or even thousands of small metabolically active molecules by a high sample-processing potential, paving the way for hypothesis-generation studies ideally suitable for complex disease scenarios, such as NAFLD. 16 Therefore, we propose a urinary metabolic profiling approach on a group of 31 pediatric NAFLD patients, enrolled in a VSL#3 RCT, employing high-resolution proton NMR ( 1 H-NMR) spectroscopy in combination with multivariate data analysis. The NAFLD urinary metabolic profile were interpreted in terms of clinical patient, treatment and chronology pattern correlations. We found that VSL#3 treatment induced changes in NAFLD urinary metabolic phenotype mainly represented by the host amino-acid metabolism (that is, valine, tyrosine, 3-amino-isobutyrate or β-aminoisobutyric acid (BAIBA)), nucleic acid degradation (pseudouridine (psi)), creatinine metabolism (methylguanidine (MG)) and in the gut microbial amino acid (valine) catabolism (as represented by 2-hydroxyisobutyrate (2-HIB)).
MATERIALS AND METHODS

Study design
The study population consisted of 31 children out of the 44 who participated in a RCT in order to evaluate the beneficial effects of VSL#3 in obese children with NASH described in detail elsewhere. 15 The study was registered at Clinical Trials.gov (NCT01650025). Briefly, we performed a parallel-arm double-blind RCT of VSL#3 vs placebo, which were provided by VSL Pharmaceuticals Inc. (Towson, MD, USA), in obese children with NAFLD enrolled at 'Bambino Gesù Children's Hospital'. Overweigh was diagnosed as BMI485th percentile, while obesity was diagnosed as BMI495th percentile, respectively, according to CDC (http://www.cdc.gov/ obesity/childhood/basics.html). The diagnosis of NAFLD was based on a combination of physical findings at examination, elevated alanine aminotransferase (ALT) levels (up to 40 UI l − 1 ) and ultrasonographic evidence of hepatic steatosis as well as histological evaluation of liver biopsies obtained at entry by an expert pathologist. 17 The Hospital Ethics Research Committee approved the study, in accordance with the Declaration of Helsinki (as revised in Seoul, Korea, October 2008), and written informed consent was obtained by parents of the enrolled patients. Collection of anthropometric data, biochemical and ultrasound data were performed at baseline, after 1 and 4 months from the beginning of the trial. Sample size was calculated and RCT was designed as previously described. 15 Briefly, children were randomized to receive in blinded manner 1 sachet per day of VSL#3 or placebo if the subject's age was o10 years. Two sachets of VSL#3 or placebo were administered in children aged 410 years. A computer-generated randomization sequence assigned participants in a 1:1 ratio to treatment with VSL #3 or placebo. Treatment duration was for 4 months. Patients enrolled in both arms, treating physicians and study coordinators were blinded to treatment as sachets provided were identical as was the visual aspect and taste of the study agent and the placebo. The envelopes were numbered, and all investigators were blinded for all the duration of the study. A low-calorie diet combined to a moderate program of aerobic exercise was prescribed to all patients during the entire study. See previous study for more details. 15 Compliance was monitored through monthly phone calls and visits. Complete medical histories, including adverse events, were recorded for all participants. Compliance to treatment was 490% in both the groups (mean values of 93% vs 94%).
Anthropometric and biochemical parameters
Anthropometric measurements and blood biochemical tests, including total and active GLP-1 assessment, have been performed as reported in the previous study, 15 and the data obtained at t 0 , t 1 and t 2 are herein reported to correlate their variations with the changes of urinary metabotypes at the same time points. All blood samples were collected in the early morning after an overnight fast.
Urine sampling for NMR-based metabolomics
Early morning urine samples were collected at home and processed in the laboratory by 2 h. In detail, 5-ml urine samples were replaced in 15-ml Falcon tubes (Corning, Tewksbury, MA, USA) containing a solution at 0.05% sodium azide final concentration to avoid microbial contamination and frozen at − 80°C until 1 H-NMR spectroscopy analysis. Urinary metabolic profiles (metabotypes) were generated from 31 NAFLD children, evaluated by NMR spectroscopy on urine at baseline (t 0 ), 1 (t 1 ) and 4 months (t 2 ) after dietary intervention with placebo or with VSL#3 supplementation. 1 
H-NMR spectroscopy of urine
Urine samples were centrifuged at 11 000 g for 15 min at 4°C. Sixtymicroliters of a 3-trimethylsilyl-propionic-2,2,3,3-d4 acid (TSP) in cold phosphate-buffered saline-D 2 O solution (2 mmol l − 1 final concentration) were added, as internal standard (IS), to 600 μl of centrifuged urine samples. The pH of urine was measured and adjusted at pH 7 by adding NaOH or HCl. 1 H-NMR spectra were acquired at 298 K using a Bruker AVANCE 400 spectrometer (Bruker BioSpin GmbH, Karlsruhe, Germany) equipped with a magnet operating at 9.4 Tesla and at 400.13 MHz for 1 H frequency. The NMR acquisition parameters are reported elsewhere. 18 Signal assignments were achieved by standard two-dimensional (2D) 1 
H-1 H Correlation Spectroscopy, Total Correlation Spectroscopy, 1 H-13 C Heteronuclear Single Quantum Correlation and Heteronuclear Multiple
Bond Correlation on selected samples and confirmed by literature comparison. [19] [20] [21] One-dimensional NMR spectra were processed and quantified by using the ACD Lab 1D-NMR Manager ver. 12.0 software (Advanced Chemistry Development, Inc., Toronto, ON, Canada), whereas 2D-NMR spectra were processed by using Bruker Top Spin ver. 3.1 (Bruker BioSpin GmbH). The NMR spectra were manually phased, baseline corrected and referenced to the chemical shift of the TSP methyl resonance at δ 0.00. The quantification of metabolites was made by comparing the specific signal integrals to the IS TSP integral. Metabolite levels were expressed as μmol mmol − 1 creatinine, using the creatinine methylene group signal at 4.05 p.p.m. as a reference.
Spectral processing and multivariate analysis
Multivariate data analysis was carried out using in-house written functions operating under Matlab R2012b environment (The MathWorks, Inc., Natick, MA, USA). Spectral data were mean-centered and Pareto-scaled before analysis. Principal components analysis (PCA) was used as a preliminary analysis to explore inherent clustering and to identify outliers. To investigate the VSL#3 effect, analysis of variance (ANOVA)-Simultaneous Component Analysis (ASCA) was applied on urinary 1 H-NMR-based metabolic profiling according to Smilde et al. 22 by partitioning the overall variation present in the experimental data into individual contributions induced by the controlled factors, treatment (VSL#3+diet+exercise) and time (diet+exercise) and their interactions and by analysing the resulting matrices by Simultaneous Component Analysis (SCA), as previously described. 23 Accordingly, ASCA was accomplished by comparing the sum of squares of each of the effect matrices (which is taken as a measure of the effect of the design terms) with its distribution under the null hypothesis, non-parametrically estimated by means of permutation tests. 22 Univariate statistical analysis All statistical analyses were performed using Sigma plot v. 11.0 (Systat Software Inc., San Josè, CA, USA). Shapiro-Wilk test was used to verify the normality of distribution of continuous variables. The two-way repeatedmeasures ANOVA were used when data were normally distributed to evaluate the effects of treatment, time or time-treatment interactions, and Holm-Sidak method was used for all pairwise multiple comparison procedures. Kruskal-Wallis one-way variance analysis of rank and Mann-Whitney U tests were used for not normally distributed data. A probability level of Po0.05 was considered to be statistically significant. Pearson and Spearman (normal and non-normal distribution, respectively) correlation analyses were used to assess the correlations among continuous variables.
RESULTS
Effects of recommended low-calorie diet and aerobic exercise and VSL#3-associated supplementation on BMI and biochemical features
Of the 116 subjects who signed informed consent, 59 underwent screening procedures and 57 were excluded at the screening. Forty-eight patients out of the 59 screened met the inclusion criteria and were randomly assigned to VSL#3 or placebo treatment. However, only 44 children (22 VSL#3 and 22 placebo) completed the study (Supplementary Figure S1 ). Among these, urine from 31 children were collected. Table 1 gives the baseline anthropometric and blood biochemical measurements of the 31 children randomized to VSL#3 (n = 15, 8 male and 7 female) and placebo (n = 16, 9 male and 7 female). Age of children was median 11 (interquartile range (IQR) 10-12) and 10 (IQR 9-12) years for the placebo-and VSL#3-treated groups, respectively. Table 1 reports the data of BMI and blood biochemical measurements at t 0 , t 1 and t 2 . No significant variation between the variables of the two randomized groups at t 0 was found, confirming that the two groups were homogeneous at baseline. Statistical univariate data analysis revealed decreases in BMI (P = 0.05), aspartate aminotransferase (AST; P = 0.002), fatty liver scores (P o0.001), total GLP-1 and active GLP-1 form (P o 0.001) between the VSL#3-and placebo-treated groups a t 2 . Parametric and non-parametric ANOVA showed significant variations of BMI (P = 0.037), AST (P = 0.010) and total GLP-1 and active GLP-1 (P o 0.05) form in the VSL#3-treated group during the time course of treatment.
Effects of recommended low-calorie diet/aerobic exercise and VSL#3-associated supplementation on urinary metabolic profiles The metabolomic analysis was performed on urinary samples collected at all time points (t 0 , t 1 and t 2 ) from 15 and 16 children, randomized to VSL#3 and placebo treatment, respectively. A typical urine 1 H-NMR spectrum from NAFLD children is reported in Figure 1 .
Forty-eight metabolites were identified by 2D-NMR experiments and quantified by integration of the resonance area. Fifteen resonances not univocally assigned (unknown, U1-U15) were integrated and considered by multivariate analysis ( Supplementary  Table S1 ). First, principal components analysis model and comparison by univariate parametric and non-parametric tests of data obtained at t 0 showed no gender-dependent clustering or metabolite changes. The different contributes due to VSL#3 treatment ('treatment' effect) (P = 0.047) and to lifestyle ('time' effect) (P = 0.028) was evaluated by exploring the whole data set by ASCA. No statistically significant effect due to the 'time'/ 'treatment' interaction was found, as showed by ASCA analysis to model the variation in the two corresponding 'treatment' and 'time' matrices (Supplementary Figure S2) .
The 'treatment' factor scores, showing a significant effect of the VSL#3 treatment on the Simultaneous Component 1 (SC1) scores, are reported in Figures 2a and b . In Figure 2c , the 'time' factor scores showed a monotone increase from t 0 to t 2 along the SC1. Conversely, 'time' factor scores on the SC2 showed an initial increase and a subsequent decrease of the time profile. The loadings of the significant metabolites for either time or treatment models are displayed by a heatmap (Figure 2d ), in which colors define the change versus (blue/decrease, red/increase and white/ not significant changes). The statistically significant urinary metabolic signature for the VSL#3 treatment was represented by decreased levels of valine, BAIBA, unidentified organic acids (that is, U3, U4), 2-HIB, MG, tyrosine and psi (Figure 2d ). The 'time' effect on SC1 loadings was characterized by increased levels of 4deoxyerithronate, alanine, lysine, N-acetylglutamine, acetate and two unidentified metabolites (that is, U3, U12) and by decrease in bile salts, 2-HIB and urocanate. The 'time' effect on SC2 loadings was characterized by a profile showing time-dependent biphasic changes of urocanate, U12 and hippurate (Figure 2d ).
The levels of the statistically significant metabolites identified by ASCA model for VSL#3 treatment and time effect at t 0 , t 1 and t 2 are reported in Table 2 . Parametric and non-parametric ANOVA tests at t 2 confirmed the VSL#3 treatment-dependent metabolic profiles revealed by ASCA, showing a decrease in valine (P = 0.031), tyrosine (P = 0.004), BAIBA (P = 0.017) and psi (P = 0.010) levels, compared with the placebo group (Table 2) . Interestingly, a statistically significant 'time/treatment' effect on valine levels (P = 0.037) was found. On the contrary, BAIBA levels were unaffected during the time course in VSL#-treated children and significantly increased at t 2 vs t 0 in the placebo group, hence indicating this metabolite as a 'treatment' factor. Table 1 . Anthropometrical and biochemical measurements of the children with NAFLD randomized to placebo (n = 16; males = 9) and VSL#3 (n = 15, males = 8) at baseline (t 0 ), 1 (t 1 ) and 4 (t 2 ) months Urinary metabolic profiling in VSL#3-treated NAFLD children Two-way ANOVA showed that 2-HIB levels significantly decreased during the time course (t 2 vs t 1 , P = 0.026; t 2 vs t 0 , P = 0.006) in the VSL#3 group and at t 2 vs t 0 (P = 0.003) in the placebo group. The difference between VSL#3 and placebo 2-HIB levels was statistically significant at t 1 (P = 0.045), corroborating the 2-HIB as a factor indicative of both 'treatment' and 'time' effects, as indicated by the ASCA model. On the other hand, hippurate levels showed a biphasic behavior (characterized by an increase at t 1 and a decline at t 0 and t 2 ), in both the treatment groups. The MG levels, which in the ASCA model resulted in significant increases at t 2 , compared with t 0 in the VSL#3 group, displayed no statistically significant differences by univariate ANOVA. This finding, as well as the lack of correlations with other parameters, was interpreted as a MG inter-individual variability in VSL#3 patients. Bile salts showed similar decreasing t 0 − t 2 patterns in both the treatment and placebo groups. On the contrary, alanine, lysine, acetate and 4-deoxyerythronate levels significantly increased only in the placebo group. The parametric and nonparametric univariate analyses confirmed metabolite level changes along 'time' factor effect, consistently with the ASCA model: increases in 4-deoxyerythronate (P = 0.006, mainly evident within placebo group at t 2 vs t 0 ), N-acetylglutamine (P = 0.001), acetate (P = 0.014), and decrease in 2-HIB levels (P o 0.001) ( Table 2) . Changes of hippurate and urocanate levels resulted statistically significant for 'time' effect comparing t 2 vs t 1 (P = 0.013 and P = 0.031, respectively), while hippurate levels resulted lower in the VSL#3 vs placebo group at t 2 (P = 0.041) ( Table 2) . Tyrosine levels were significantly correlated with valine (R = 0.698; P o0.001) ( Figure 3 ) and BAIBA (R = 0.429; P = 0.016) levels. The 2-HIB was significantly correlated with psi (R = 0.405; P = 0.023), U4 and U5 (R = 0.494; P = 0.005 and R = 0.413; P = 0.021, respectively), but not with BAIBA, while BAIBA was significantly correlated with U4 and U5 (R = 0.631; P o0.001 and R = 0.392; P = 0.029, respectively).
Statistical correlation at t 2 between metabolite levels and clinical or biochemical parameters Clinical (BMI, ultrasound steatosis score) and biochemical parameters (AST, ALT and active GLP-1) were correlated with the ASCA model statistically significant metabolite profiles (that is, BAIBA, tyrosine, psi, 2-HIB, MG, U3 and U4). BMI values, correlating with steatosis score (R = 0.415, P = 0.02), positively correlated with the organic acid U4 (R = 0.36, P = 0.045); ALT positively correlated with tyrosine (R = 0.399, P = 0.026); active GLP-1 negatively correlated with steatosis scores (R = − 0.49, P = 0.005), BAIBA (R = − 0.51, P = 0.003) and tyrosine levels (R = − 0.41, P = 0.021).
DISCUSSION
A recent RCT has provided the first human clinical evidence demonstrating that a brief course of supplementation with VSL#3 significantly improves fatty liver and BMI in children with NAFLD, associated with a significant trend toward increasing values of total and active GLP-1 in the VSL#3 group. 15 The present study is an extension of same trial with the aim to identify urinary The results obtained by the metabolomic analysis substantiated the improvements previously observed in the original larger cohort 15 regarding BMI, liver fatty acid score and ALT levels at t 1 in VSL#3-treated group and confirmed that VSL#3 supplementationdependent increase in total and active GLP-1 plasma levels may suggest a role of this peptide in decreaseing BMI and ultrasound steatosis score.
The application of a multivariate model, such as ASCA, on urinary NMR-based data allowed us to distinguish the contributes of two effects (treatment and lifestyle intervention) measured at t 0 , t 1 and t 2 . Indeed, ASCA can be considered an extension of ANOVA to multivariate data and is particularly useful to evaluate the significance of the effect of one or more factors and their interactions on the multivariate experimental data. To interpret the results relative to 'time' effect, it is important to take into account that data are the resulting of the comparison among data matrices obtained at t 0 , t 1 and t 2 , as a sum of placebo and VSL#3 treatment group data. The VSL#3 treatment induced a change in the urinary metabotype of children with NAFLD mainly characterized by decreased levels of tyrosine, valine, BAIBA, psi and MG. In the absence of an impaired renal functionality, a decreased urinary excretion of branched chain (BCAA; for exampe, leucine, valine) and aromatic amino acids (AAA; for example, tyrosine) can be likely referred to as changes of their serum levels, hence suggesting an effect of VSL#3 treatment on the regulation of amino-acid metabolism.
Indeed, high serum levels of AAA and BCAA have been associated with clinical risk factors of metabolic syndrome associated withobesity. 24 A recent study performed on 7098 young adults revealed an association of homeostasis model assessment-insulin resistance (HOMA-IR) with the serum NMRbased metabolic signature characterized by high levels of BCAA and AAA. Although, the origin of the association between high AAA, BCA serum levels and insulin resistance was not fully clarified, high serum amino-acid levels contribute to characterize the metabolic signature of insulin resistance. 25 Our results showed that tyrosine and valine were strongly correlated ( Figure 3 ) and decreased in VSL#3-treated children, Urinary metabolic profiling in VSL#3-treated NAFLD children compared with the placebo group at t 2 . No significant correlation between urinary amino-acid levels and HOMA-IR was found, while a significant inverse correlation between circulating levels of GLP-1 and tyrosine was detected. These results suggest that the effect of VSL#3 administration on the amino-acid metabolism could depend on an effect more modulated by the increasing GLP-1 levels rather than an improvement of insulin sensitivity.
GLP-1 is mainly involved in stimulating insulin secretion and in limiting postprandial glucose excursions. Furthermore, it appears to be a physiological regulator of appetite and food intake, and it has been suggested that a decreased secretion of GLP-1 may contribute to the development of obesity. 26 Among the metabolic signatures associated with 'treatment' effect, we found that psi, BAIBA and 2-HIB decreased levels were associated with lower levels of tyrosine and valine in the VSL#3treated group. Psi is a modified nucleoside that is found in ribosomal and transfer RNA and is posttranscriptionally produced. 27 The urinary psi levels mainly originate from ribosomal and transfer RNA degradation, reflecting RNA turnover 28 and hence protein turnover, as recently reported. [29] [30] [31] Actually, these metabolic incomes could be increased by oxidative modifications occurring in pediatric NAFLD, [32] [33] including high dietary energy intake. 33 It is now well recognized that, in humans, NAFLD is associated with increased IP and small intestinal bacterial overgrowth, and these factors are associated with the severity of the liver tissue damage. 34 In NAFLD patients, the gut has been demonstrated to be 'leaky' because of a tight junction disruption process that might explain the intestinal bacterial contribution to liver disease progression. 35 We hypothesize that VSL#3 effects in NAFLD are linked to the modulation of gut microbiota regulating IP, liver oxidative stress and fatty liver through the stimulation of secretion of GLP-1 from entero-endocrine L cells. Therefore, the decrease of urinary levels of 2-HIB and BAIBA in the VSL#3-treated NAFLD children, showing improved BMI, is remarkable. In fact, an increased urinary excretion of 2-HIB, associated with a low urinary excretion of hippurate and N-methylnicotinate, has been reported as a typical urinary metabotype of adult obese individuals, lost after bariatric surgery. 36 In a previous study by Li et al., 37 a statistical relation among 2-HIB and BAIBA with the Faecalibacterium prausnitzii population variation was found. As the urinary 2-HIB levels can originate only by gut bacteria, 38 the probioticdependent decrease in 2-HIB urinary excretion may suggest that the VSL#3 administration could modify gut microbial metabolic system in NAFLD children, hence decreasing the steatosis grade and altered liver parameters.
Our results confirmed the increased release of GLP-1 as a consequence of probiotic VSL#3 administration, resulting in NAFLD beneficial effects, in agreement with the RCT. 15 A previous mechanistic study on animal model showed that VSL#3 can modulate the gut flora composition and enhance the expression and the activity of the GLP-1. 39 The authors suggested that the beneficial effect on weight loss in diet-induced obese mice could be related to GLP-1 enteric release mediated by the gut microbial butyrate production. 39 The relationship among prebiotic and probiotic administration, changes in gut microbiota, regulation of energy balance and glucose homeostasis and elevated GLP-1 enteric release has been largely studied. 40 Interestingly, we showed that the VSL#3 treatment-dependent increase of GLP-1 was inversely correlated with urinary tyrosine and BAIBA levels. BAIBA is a catabolite of both thymine 41 and valine metabolism, and its levels depend on both gut microbial and muscle metabolism. The observed inverse correlation of BAIBA with GLP-1 levels and the positive correlation with tyrosine levels was unexpected. Indeed, in a recent large human cohort study involving 2067 random subjects enrolled in the longitudinal, community-based Framingham Heart Study, blood BAIBA levels were inversely correlated with fasting glucose, insulin, HOMA-IR, triglycerides and total cholesterol in age-and sex-adjusted analysis. 42 The authors demonstrated that the contracting muscle cells secrete BAIBA, mediating signaling processes in white adipose tissue and liver and leading to weight loss and enhanced glucose tolerance in mice. On this basis, the observed beneficial VSL#3-dependent effects on the clinical status of NAFLD children and the lower observed urinary BAIBA levels in the treated group may appear contradictory. To explain this apparent discordance, it is important to take into account that during the VSL#3 treatment a significant rise of GLP-1 forms, compared with unchanged BAIBA levels, were found. On the contrary, in the placebo group a slight significant increase in BAIBA levels associated with no significant changes of GLP-1 forms was observed. These results suggest that diet and physical activity positively affect BAIBA production, although valine and tyrosine values were higher in the placebo group compared with the VSL#3-treated children, with no improvement in HOMA-IR and fatty liver indexes. Thus our results suggest that the VSL#3 treatment, through GLP-1 rising, could regulate muscle mitochondrial metabolic flux towards the complete degradation of valine with final production of succinyl-CoA, an intermediate of citrate cycle for energy metabolism. On the other hand, we cannot exclude that VSL#3 treatment may influence the pyrimidine salvage pathway, because the levels of BAIBA can also originate from the thymine metabolism.
Further investigations are required to understand the relationship between circulating levels of GLP-1, urinary BAIBA levels and VSL#3 treatment effects in NAFLD children in order to analyze gut microbiota effects on metabolite profiles.
In conclusion, our findings on 31 children participating in the VSL#3 clinical trial confirm the clinical evidence demonstrating that a brief course of supplementation with VSL#3 significantly improves fatty liver and BMI and provide differentially expressed urinary metabolites ('biomarkers') in children with NAFLD, as compared with the placebo group undergoing standard lifestyle regimen for 4 months. The correspondent VSL#3 treatmentdependent urinary metabotypes of NAFLD children show an effect on BAA and AAA metabolism, turnover of r-RNA and t-RNA related to oxidative stress and finally on few pathways of gut microbiota metabolism. Furthermore, our results suggest that some of the metabolic effects of VSL#3 treatment can be mediated by rising of circulating active GLP-1 forms.
